Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;10(Suppl 2):S306-10.
doi: 10.4103/0973-1296.133285.

Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2

Affiliations

Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2

Ashok Kumar Pandurangan et al. Pharmacogn Mag. 2014 Apr.

Abstract

Colon cancer (CRC) is a serious health problem through worldwide. Development of novel drug without side effect for this cancer was crucial. Luteolin (LUT), a bioflavonoid has many beneficial effects such as antioxidant, anti-inflammatory, anti-proliferative properties. Azoxymethane (AOM), a derivative of 1, 2-Dimethyl hydrazine (DMH) was used for the induction of CRC in Balb/C mice. CRC was induced by intraperitoneal injection of AOM to mice at the dose of 15 mg/body kg weight for 3 weeks. Mouse was treated with LUT at the dose of 1.2 mg/body kg weight orally until end of the experiment. The expression of inducible nitric oxide synthase (iNOS) and cyclooxygense (COX)-2 were analyzed by RT-PCR and immunohistochemistry. The expressions of iNOS and COX-2 were increased in the case of AOM induction. Administration of LUT effectively reduced the expressions of iNOS and COX-2. The present study revealed that, LUT suppresses both iNOS and COX-2 expressions and act as an anti-inflammatory role against CRC.

Keywords: Azoxymethane; COX-2; Luteolin; colon cancer; iNOS.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Luteolin reduced the levels of ALP and LDH Units: (A): Activity of ALP (mU/mg protein), (B): activity of LDH (μM of pyruvate liberated/min/mg protein). Values are expressed as mean ± S.D. for 6 mice in each group. aControl Vs AOM, bAOM Vs AOM+LUT, ns-non significant P <0.05
Figure 2
Figure 2
Luteolin decreases the expression of iNOS (a): (Control) Normal expression of iNOS, (b): (AOM) high expression of iNOS (brown color) was observed, (c): (AOM+LUT) lesser degree of expression of iNOS was noticed, (d): (LUT) Expression was similar to that of control. -> shows the expression of iNOS. (2B), Quantification of the expressions of iNOS. Values are expressed as mean ± S.D. Comparisons: aControl Vs AOM, bAOM Vs AOM+LUT, ns-non significant *P < 0.05. (2C): RT-PCR analysis of iNOS. The band was detected at the 194 bp and Actin was at 842 bp. The quantification of iNOS was normalized with Actin shown in 2D
Figure 3
Figure 3
Luteolin decreases the expression of COX-2 (a): (Control) Normal expression of COX-2, (b): (AOM) high expression of COX-2 (brown color) was observed, (c): (AOM+LUT) lesser degree of expression of COX-2 was noticed, (d): (LUT) Expression was similar to that of control. -> indicates the expression of COX-2 protein. (3B): Quantification of the expression of COX-2. Values are expressed as mean ± S.D. Comparisons: aControl Vs AOM, bAOM Vs AOM+LUT, ns-non significant *P < 0.05. (2C): RT-PCR analysis of COX-2. The band was detected at the 247 bp and Actin was at 842 bp. The quantification of COX-2 was normalized with Actin shown in 3D

Similar articles

Cited by

References

    1. Pandurangan AK. Potential targets for the prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev. 2013;14:2201–5. - PubMed
    1. Shike M, Winawer SJ, Greenwald PH, Bloch A, Hill MJ, Swaroop SV. Primary prevention of colorectal cancer: WHO collaborating center for prevention of colorectal cancer. Bull World Health Organ. 1990;68:377–85. - PMC - PubMed
    1. Thun MJ, Namboodiri MM, Heath CW., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;1325:1593–6. - PubMed
    1. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609–14. - PubMed
    1. Macejová D, Brtko J. Chemically induced carcinogenesis: A comparison of 1-methyl-1-nitrosourea, 7,12-dimethylbenzanthracene, diethylnitrosoamine and azoxymethane models. Endocr Regul. 2001;35:53–9. - PubMed